Diker Management LLC Takes $369,000 Position in Artivion, Inc. $AORT

Key Points

• Diker Management LLC acquired a stake in Artivion, Inc. by purchasing 15,000 shares valued at approximately $369,000, making it the company's 23rd largest holding.
• Artivion reported earnings per share of $0.24 for the last quarter, exceeding analysts’ expectations by $0.13, and its revenue increased by 15.3% year-over-year.
• Multiple brokerages have upgraded Artivion’s ratings and price objectives recently, with a consensus rating of "Buy" and an average price target of $40.63.

Diker Management LLC bought a new stake in Artivion, Inc. (NYSE:AORT - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 15,000 shares of the company's stock, valued at approximately $369,000. Artivion comprises 0.4% of Diker Management LLC's holdings, making the stock its 23rd biggest holding.

Other institutional investors have also modified their holdings of the company. Fred Alger Management LLC acquired a new stake in shares of Artivion in the 1st quarter worth about $2,969,000. Parkman Healthcare Partners LLC bought a new stake in Artivion during the 1st quarter valued at $2,744,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Artivion by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company's stock worth $580,000 after acquiring an additional 1,032 shares during the period. Bridger Management LLC bought a new position in shares of Artivion in the first quarter worth $1,580,000. Finally, AQR Capital Management LLC grew its stake in shares of Artivion by 8.8% in the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company's stock worth $862,000 after purchasing an additional 2,823 shares in the last quarter. Institutional investors own 86.37% of the company's stock.

Insider Buying and Selling

In other Artivion news, insider John E. Davis sold 10,802 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company's stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO James P. Mackin sold 12,500 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company's stock, valued at approximately $36,089,776.56. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,858 shares of company stock worth $3,692,629. Company insiders own 8.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Oppenheimer restated an "outperform" rating on shares of Artivion in a research report on Friday, August 8th. Canaccord Genuity Group increased their price objective on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. LADENBURG THALM/SH SH lowered shares of Artivion from a "buy" rating to a "neutral" rating and raised their price objective for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Finally, Wall Street Zen upgraded Artivion from a "hold" rating to a "buy" rating in a research report on Monday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $40.63.

Artivion Price Performance

Shares of NYSE AORT traded down $0.80 during midday trading on Monday, reaching $39.91. The company's stock had a trading volume of 103,391 shares, compared to its average volume of 441,767. Artivion, Inc. has a one year low of $21.97 and a one year high of $45.07. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -95.05 and a beta of 1.69. The company has a 50 day moving average price of $37.46 and a 200 day moving average price of $30.33. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.13. The firm had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business's revenue for the quarter was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.